BioCardia Business Summary

BioCardia, Inc. (BCDA) is a clinical-stage regenerative medicine company that generates revenue through a hybrid model of biotherapeutic delivery system sales, strategic licensing agreements, and clinical trial reimbursements, such as those from the Centers for Medicare and Medicaid Services (CMS). The company operates through three primary business segments: the CardiAMP autologous cell therapy platform, the CardiALLO allogeneic cell therapy platform, and its proprietary biotherapeutic delivery systems, including the Helix transendocardial delivery catheter and Morph vascular navigation tools. As of March 2026, BioCardia is focused on advancing its Phase III CardiAMP HF trial for ischemic heart failure and seeking FDA De Novo 510(k) clearance for its Helix platform to transition toward a "platform-as-a-service" revenue stream. Its primary direct competitors include Mesoblast, Verve Therapeutics, Elutia, and BioRestorative Therapies; BioCardia distinguishes itself in this landscape as a specialized micro-cap player utilizing a unique point-of-care autologous approach that minimizes the logistical complexities of off-site cell processing. The company is led by President and CEO Peter Altman, Ph.D., who has steered the firm since 2002 and previously served as the founding CEO of CareDx (CDNA). The leadership team includes Chief Financial Officer David McClung, Chief Technology Officer Debby Holmes-Higgin, and Senior Vice President of Devices Edward Gillis. BioCardia was co-founded by Dr. Simon Stertzer, a Professor Emeritus at Stanford University and a pioneer in interventional cardiology who performed the first coronary angioplasty in the United States. The Board of Directors is chaired by Andrew Blank and recently added Marvin Slosman, the current CEO of InspireMD, to bolster its commercialization and regulatory expertise. Notable institutional influence is maintained through the involvement of the Maryland Stem Cell Research Fund, which supports the company’s clinical development, alongside a board composed of seasoned veterans from major healthcare entities like Johnson & Johnson and GE Healthcare.